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Abstract 
Intraplaque hemorrhage accelerates atherosclerosis via oxidant stress. Normally, macrophages 
scavenge hemoglobin-haptoglobin (HbHp) complexes via CD163, and this provokes secretion 
of the anti-inflammatory atheroprotective cytokine IL10. We therefore tested the hypothesis 
that HbHp complexes may drive monocyte differentiation to an atheroprotective phenotype. 
Examination of macrophage phenotype in hemorrhaged atherosclerotic plaques revealed a 
novel hemorrhage-associated macrophage population (HA-mac), defined by high levels of 
CD163 but low HLA-DR. HA-mac contained more iron, a pro-oxidant catalyst, but 
paradoxically had less oxidative injury, measured by 8-oxo-guanosine content. Differentiating 
monocytes in vitro with HbHp complexes reproduced the CD163high HLA-DRlow HA-mac 
phenotype. These in vitro HA-mac cells cleared Hb more quickly and consistently showed less 
hydrogen peroxide release, highly reactive oxygen species and oxidant stress, and increased 
survival. Differentiation to HA-mac was prevented by neutralising IL10 antibodies, indicating 
that IL10 mediates autocrine feed-back in this system. Non-linear dynamical modelling 
showed that an IL10-CD163 positive feedback loop propelled a discrete HA-mac lineage. 
Simulations further indicated an all-or-none switch to HA-mac at threshold HbHp, and this  
was experimentally verified. These data demonstrate a novel atheroprotective (HA-mac) 
macrophage subpopulation in response to intra-plaque hemorrhage, and raise the possibility 
that therapeutically reproducing this macrophage phenotype may be cardio-protective.  
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Introduction 
Atherosclerotic intraplaque hemorrhage is an important contributor to lesion development 
and destabilization (1-3)(4;5). In the carotid, hemorrhage promotes progression and clinical 
symptoms (6). Furthermore, coronary intralesional hemorrhages are tightly associated with 
thrombosis (7). Mechanisms for atherogenicity of hemorrhage include the delivery of 
cholesterol-rich erythrocyte membranes and hemoglobin-derived iron, which can catalyse 
hydrogen peroxide conversion into highly reactive oxygen species (hROS)   (1;2).  Thus a 
clearer understanding of macrophage responses to intraplaque hemorrhage is critical.  
 
Hemoglobin (Hb) is principally cleared by complexing with haptoglobin (Hp), followed by 
uptake via CD163, a macrophage scavenger receptor (3;8). The association of Hb with Hp is 
normally crucial to its binding to CD163, although in diabetes there is evidence for Hp-
independent CD163 binding of glycosylated Hb (3;9).  The importance of Hp is strongly 
supported by the association of Hp genotypes with many forms of vascular disease (10;11). 
As a consequence of CD163 binding, HbHp induces interleukin 10 (IL10) and heme 
oxygenase-1 (HO-1), which are anti-inflammatory  and atheroprotective (12-14). However, it 
is possible that CD163 functions primarily as an endocytic receptor, with down-stream 
signalling being induced by internalised heme (13). Taken together, experimental studies 
favour a protective role of CD163, and CD163 expression in atherosclerotic tissues may 
therefore represent an adaptation limiting the atherogenicity of plaque hemorrhage.  
 
Hypercholesterolaemia-sensitive monocyte subsets (CD14highCD16null & CD14lowCD16pos)  
have been described in blood (15;16). However, macrophage differentiation to separate 
phenotypes occurs primarily in response to tissue microenvironmental influences, which in 
plaques include oxidatively modified low density lipoproteins (OxLDL). Indeed, Kruth has 
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recently published evidence that macrophage subsets defined by the presence or absence of 
CD14 can be found in human atherosclerotic tissue (17).  
 
We tested the hypothesis that intraplaque hemorrhage results in monocyte differentiation to 
macrophages specialised for safe hemoglobin disposal. We show that culprit atherosclerotic 
plaques contain a novel anti-oxidant hemorrhage-associated macrophage subset (HA-mac) 
defined by high CD163 and low HLA-DR, and distinct from proinflammatory lipid core 
macrophages. HA-mac could be generated in vitro by culturing monocytes with HbHp 
complexes, through a mechanism centered on an IL10 autocrine feedback loop. Our data 
indicate that monocytes entering atherosclerotic plaques may be adaptively modelled by 
plaque hemorrhage.  Understanding this differentiation pathway may allow intervention to 
induce protective macrophage differentiation therapeutically.
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Methods 
Pathology, immunohistochemistry, confocal, image analysis 
Human plaques were from a series of paraffin-embedded plaques that derive from  
consecutive West of Scotland hospital autopsies, and have already been fully described 
(18;18). Tissues were studied with consent of next of kin for autopsy and for use of tissues 
for research, Local Research Ethics Committee (LREC) and Central Office for Research 
Ethics Committees (COREC) approved the research, .and the tissues and site were registered 
under the UK Human Tissue Act. Exclusion criteria were severe sepsis or hematological 
malignancy. 
 
To study the effects of hemorrhage on macrophages, we selected for study one lesion per 
patient with both evident hemorrhage and macrophage infiltrates on H&E sections. 
Consistent with the literature (7;19;20), these lesions were thrombosed due either to rupture 
(6 cases) or intimal erosion (2 cases). Crosschecking with clinical information indicated that 
the selected plaques corresponded to a tightly defined group of fatal myocardial infarction, 
occurring within 48 hours of event onset (18). As a consecutive hospital series, this cohort is 
very different to studies of selected autopsies for community sudden cardiac death (1;21).  
 
For immunostaining, sections were deparaffinised, microwaved for 20 minutes in citrate 
buffer (600W), blocked in serum and peroxidase-blocked. Sections were incubated with anti-
CD163 (clone 10D6, Novocastra, Newcastle upon Tyne, UK), then with biotinylated anti-
mouse secondary (1:200, Dako Ltd, Ely, UK) and streptavidin-alkaline phosphatase (1:100, 
Roche Diagnostics Ltd., Lewes, UK). Color was developed with Vector Blue (Vector 
Laboratories Ltd., Peterborough, UK). Sections were then incubated with anti-HLA-DR 
(clone CR3/43, Dako), which was detected with polymer-peroxidase kit (A. Menarini 
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Diagnostics UK, Wokingham, UK) followed by color development with amino-ethyl-
carbazole (AEC, Vector Laboratories). CD68 was probed with antibody clone PG-M1 (Dako) 
and detected with polymer-peroxidase kit (Menarini) and color was developed with ??-???-di-
amino-benzidine (DAB, Sigma-Aldrich, Poole, UK) and hematoxylin counterstaining 
(Pioneer Research Chemicals, Colchester, UK). For CD163/iron dual staining, sections were 
probed for CD163 as above with polymer immunoperoxidase?AEC and counterstained with 
??????. Erythrocytes were detected with anti-glycophorin C (clone Ret40F, Dako), then 
detected with polymer immunoperoxidase / AEC as above. 8-oxo-guanosine was specifically 
probed with goat polyclonal IgG (1:1000 dilution in PBS, Calbiochem DR1001, Calbiochem, 
Beeston, Nottingham, UK), followed by detection with polymer-
peroxidase/DAB/hematoxylin as above. Negative controls [pre-immune goat serum at 
equivalent concentration, and adsorption with 8-oxo-guanosine (Calbiochem)] were without 
brown staining. 
 
Counting of CD68-positive macrophages (in total 9326) on CD163/HLA-DR dual-stained 
sections was performed manually. We measured the shortest straight line distance from the 
macrophages to the specified feature (lipid core, hemorrhage, or CD34-positive neovessels) 
with an eyepiece graticule. . Neovessels were defined as CD34-bounded spaces of any size. 
Iron was assessed semi-quantitatively on a standard hemochromatosis histology scale of 0 (no 
iron) to 3+ (maximum iron), where 3+ is equivalent to the images shown.  
 
Quantification of HO-1 and 8-oxo-G intensity was by minor adaptation of validated image 
morphometry protocols (22;23),  using Image J (a PC-compatible version of NIH-Image) 
rather than NIH-Image (Macintosh version). Digitally captured RGB images (Olympus 
Camedia C5050, Olympus, Watford, UK) were RGB split, after which the blue channel was 
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subtracted from the red, producing a black and white image of brown density. This was 
measured by the Image J intensity histogram function to generate the arithmetic mean 
intensity. A region of interest was manually drawn to measure only parts of the image that 
included macrophages, and ????????????????????????????????????????????????er area. Mean 
density units of intensity were then expressed as a continuous variable. Since normality 
testing by Kolmogorov-Smirnov indicated a non-Gaussian distribution, significance testing 
was by Mann-Whitney.
 
Confocal microscopy 
For confocal detection, we substituted fluorescent secondary antibodies for the enzyme-
labelled second layers, with staining and storage in the dark. Primary antibodies, blocking 
and microwaving were as above. Anti-CD163 (clone 10D6) was detected with goat-anti-
mouse AlexaFluor 647 (Molecular Probes, Invitrogen, Paisley, UK; Ex.633nm, Em. 650-
700nm); anti-HLA-DR with goat-anti-mouse AlexaFluor 568 (Molecular Probes; Ex. 568nm, 
Em. 580-610nm); and anti-CD68 with FITC-labelled KP1 (Dako; Ex.488nm, Em. 500-
535nm). Sections were counterstained for 5 mins in nuclear dye 7-actinomycin D (7-AAD, 
Molecular Probes) and mounted in 80% glycerol / 20% PBS (both Sigma-Aldrich).  We used 
a Zeiss LSM 510 Meta inverted confocal microscope, with 3 laser lines. Pinhole and unable 
filter settings were at defaults. One scan was performed using differential interference 
contrast (DIC) to define general topography. A further confocal scan was then performed at 
FITC excitation and Cy5 emission wavelengths (Ex. 488nm, Em. 650-700nm), yielding a 
selective image of 7-??????????????????????????????????????????????????Scan and 
photomultiplier settings were set to optimize signal/noise ratio for each emission wavelength. 
Processing was with Zeiss LSM Image Browser, and comprised addition of scalebars, and 
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adjustment of brightness and contrast, prior to import into Microsoft Powerpoint for assembly 
of montage Figures. 
 
In vitro macrophage cultures and reagents  
Human monocytes were isolated as described from venous blood of healthy consenting 
volunteers, following LREC approval (14;24). In brief, 50mL donor blood was collected 
aseptically, immediately citrated, and centrifuged to separate plasma from cells. Plasma was 
then recalcified to produce autologous serum. Mononuclear cells were purified by 
centrifugation through Histopaque 1077 (10771, Sigma-Aldrich) at 500G for 20 mins (24). 
In some experiments, erythrocytes were removed by dextran sedimentation (Pharmacia, GE 
Healthcare, Amersham, UK) and Percoll (Pharmacia) density gradient centrifugation (14). 
Macrophages were purified on the culture plastic by adherence incubation for 1 hour 
followed by three ???????????????????????? ??????????????????? ?????????????????????
21056, Invitrogen). These cells had >95% purity by flow cytometry for forward scatter, side 
scatter, and CD14 staining. Unless otherwise stated, macrophages were cultured for 7 days at 
approximately 105 cells per well in 24 well plates in 10% autologous donor serum, IMDM 
(10% AHS IMDM), with penicillin (100 IU.mL-1) and streptomycin (100 ?g.mL-1). 
Hemoglobin (lyophilised stabilised purified Ao ferrous hemoglobin, H0267, Sigma-Aldrich) 
and haptoglobin phenotype 1-1 (lyophilised purified, H0138, Sigma-Aldrich) were 
reconstituted in PBS at 1mg.mL-1. HbHp complexes were generated by dissolving equimolar 
amounts of Hb and Hp in growth medium. Hb and Hp were tested for endotoxin (Limulus 
amebocyte lysate, sensitivity <0.125EU/mL, LAL Pyrogent® Plus kit, Cat.No. N289, 
Cambrex, Walkersville, MD). Approximately 1 batch in 10 of each was endotoxin-positive 
and excluded from further use. Hb, Hp or HbHp complexes were added at the indicated 
concentrations to monocyte cultures immediately following purification by adherence. The 
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following antibodies, drug inhibitors or vehicle were added at concentrations indicated 10 
mins prior to the HbHp complexes: antagonistic anti-CD163 monoclonal antibodies (RM3/1, 
Bachem AG, St Helens, UK; EdHu-1, Serotec, Oxford, UK); neutralizing anti-IL10 Mab 217 
(R&D Systems); lipopolysaccharide (LPS, O111:B4), cytochalasin D, pepstatin-A, 
chloroquine (Sigma-Aldrich); interferon gamma (IFN?) (Peprotech, London, UK).  
 
Human LDL was collected from clinical apheresis supernatant and purified by 
ultracentrifugation and dialysis as before (gift of D. Patel)(25). The LDL was oxidised in 
20?M CuSO4 for 24 hours at 37?C, with oxidation validated by thiobarbituric acid and 
agarose gel electrophoresis as before (26).  
 
For flow cytometric staining, macrophages were harvested with a disposable sterile plastic 
policeman. Cells were centrifuged 13000 rpm for 60 secs in a microcentrifuge (Eppendorf, 
Fisher Scientific, Loughborough, UK), resuspended in 50?L PBS (Sigma-Aldrich), and 
stained for 20 mins at 4?C in 2 ?g.mL-1 FITC-labelled anti-CD163 (56C-FAT, Bachem). 
Isotype control was 2 ?g.mL-1 IgG1-FITC (Serotec). For double staining, the cells were co-
incubated with anti-HLA-DR-PE (clone HK14, Sigma-Aldrich) or isotype control (mouse 
IgG1-PE, Sigma-Aldrich). The cells were then washed by centrifugation in 1mL PBS, and 
resuspended in 400?L PBS for flow cytometry. The cells were read on a Coulter EpicsXL 
flow cytometer, FL1-600V, FL2-600V, 1% compensation. Data were analysed and 
presented using WinMDI (http://facs.scripps.edu/software.html). 
 
For cytokine assays, macrophages were cultured in 10% AHS-IMDM for 24 hours at 
approximately 103 cells per well in 96-well microplates (Nunc, VWR), in the presence or 
absence of 10?g.mL-1 HbHp complexes (approximately 10-7mol.L-1 complexes), 10-8mol.L-1 
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dexamethasone, or 10ng.mL-1 LPS. The supernatants were then stored at -80?C prior to 
analysis. Cytokines were measured by DuoSets® according to manufacturer?s instructions 
(R&D Systems, Abingdon, UK). 
 
For the DCF oxidant stress assay, macrophages were differentiated for 7 days in 96-well 
microplates, in either control medium or with added HbHp complexes. Macrophages were 
then loaded with 10????????-di-chloromethyl, di-hydro, di-chloro-fluorescein diacetate 
(CM-DCFDA, Molecular Probes). Cells were then stimulated with phorbol myristate acetate 
(PMA; Sigma-Aldrich; 10-7mol.L-1). Fluorescence (Ex.485±10nm, Em. 535±10nm) was 
measured at the time points indicated in a 96 well plate reader (Synergy HT, Biotek, Fisher 
Scientific) at 37?C.  
 
For peroxide assays, macrophages were differentiated and stimulated as before in 96-well 
plates, but in the presence of Amplex Red (1?g.mL-1, Molecular Probes, Invitrogen) and 
horseradish peroxidase (1:1000, Sigma-Aldrich).  Fluorescence was read after 24 hours 
(Ex.535nm, Em.590nm) 
 
Highly reactive oxygen species (hROS) exhibit electrophilic attack on the amino-moiety of 
aminophenylfluorescein (APF), which rearranges to form fluorescein (27). We validated the 
specificity of APF for HONOO?, OH?, OCl- rather than H2O2 in our own hands. To assess 
specific production of hROS, macrophages were differentiated as before in 96-well plates. 
We then added 5?mol.L-1 APF (Molecular Probes) and stimuli. After 24h, fluorescence was 
measured by microplate reader (Ex. 484nm, Em. 515-550nm) and expressed as arbitrary 
fluorescence units.  
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Supernatant Hb concentrations were measured spectrophometrically at the characteristic 
peak Hb absorbance (Soret peak, A412 nm, 100?L volume, plate reader above). Calibration 
was performed using Hb at known concentrations of 10-8, 10-7, 10-6 mol.L-1, and full 
absorption spectrum (400-700nm in 1nm intervals). 
 
siRNA 
Adherence-purified monocytes were transferred to 0.1%AHS in IMDM without antibiotics. 
Complexes were prepared from 5fmol siRNA (Dharmacon, CD163 ; scramble). These were 
complexed with 10?L Genlantis liposomes (AMS Biotechnology) for 30mins and complexes 
were then incubated with monocytes for 24h.Western blotting was with Novex precast 
system (Invitrogen). Immunodetection was in PBS, 4% non-fat milk powder 0.1% Tween-
20 (Sigma). We used a western-blot validated monoclonal antibody GHI/61 (1:1000; Santa 
Cruz) (28); anti-mouse peroxidase (1:10,000; Dako), ECL-Plus and hyperfilm (both 
Amersham). 
 
Hb was labelled with Alexa??????????????????????????? ??????????????????????????, and as 
published (13). Hb-Alexa488 was complexed with Hp and added to macrophages at culture 
day 1 at 10-7mol.L-1. Cells were also assessed by RM3/1 flow cytometry and the effects of 
RM3/1 on Hb phagocytosis was assessed. 
 
Mathematical modeling using non-linear dynamics  
Standard modelling approaches were used (29-31). The mathematical model was formed 
from a coupled pair of nonlinear ordinary differential equations describing Supplemental 
Figure S1 (http://www.amjpathol.org) [equations (1) & (2)]. The model has two variables 
[CD163] and [IL10] which describe the time course of the concentrations of the two species. 
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The rate of change of each species is determined by the production and degradation of each. 
We therefore obtain: 
d[CD163]
dt
 = CD163 Production Rate   ?   CD163 Degradation Rate 
 = 
[IL10][R]
[IL10]? kd1
   ?   k1[CD163] (1) 
d[IL10]
dt
 = IL10 Production Rate   ?   IL10 Degradation Rate 
 = 
[CD163][HbHp]
[HbHp]? kd2
   ?   k2[IL10] (2) 
where [HbHp] is a parameter indicating the HbHp concentration (in arbitrary units) and [R] 
is a parameter that describes the sensitivity of CD163 upregulation to IL10 levels. One 
possible biological interpretation is that the first term of Equation 1 represents the 
concentration of IL10 receptors available for  CD163 binding on the cell surface. 
Degradation is modelled using simple exponential decay with rates k1 and k2 . The parameters 
kd1 and kd2 determine the saturation of the production rates of IL10 and CD-163 respectively. 
These were solved numerically and graphed using Maple 11 (Maplesoft, Waterloo, Ontario, 
Canada).  Since this was a proof of concept model, it was kept as simple as possible and 
simulations used arbitrary units and illustrative values were assigned to parameters. An 
advantage to formulating a simplified model is that the steady state values can be derived 
analytically and it is possible to verify that these arbitrary choices do not affect conclusions. 
Equilibrium solutions and threshold values were obtained by algebraic rearrangement and 
graphed in Maple 11. To determine the robustness of the observed dichotomy, we ran 
simulations using a range of arbitrary parameters. These all predicted qualitatively similar (ie 
dichotomous) behavior around a threshold. To validate the model, we then experimentally 
tested the behavior it predicted. 
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Statistical Analysis 
The inverse relationship between CD163high and HLA-DRhigh macrophages in coronary 
????????????????????????????????????????????????????????????????????????????????
correction. Normality was tested by Kolmogorov-Smirnov and normally-distributed data 
were tested parametrically. The data in Table 1 appeared approximately normally distributed 
but normality testing was equivocal due to low n-values. They were therefore expressed 
parametrically as mean ± standard error (SE) but tested using a rank method (Mann-Whitney) 
which is a more stringent assessment. Where indicated, statistical testing of parametric 
continuous data was performed using ANOVA with Bonferroni correction for multiple 
simultaneous comparisons, or a two-?????????????????t-test. Statistical analysis was 
performed using Excel® (Microsoft, Seattle, WA) or SigmaStat®  (Systat, San Jose, CA). 
Exact P-values are presented to clarify the strength of the statistical differences. 
  
14 
14 
Results 
Culpr it human lesions contain a novel hemorrhage-associated macrophage 
subpopulation identified by CD163. 
We examined the effect of atherosclerotic plaque hemorrhage on macrophage phenotype,  
assessing 351 plaques from 83 consecutive autopsies (18;19). 8 had confluent intraplaque 
hemorrhage and macrophage infiltrates. Each of these was a thrombosed atherosclerotic lesion 
with a large hemorrhage and numerous macrophages (Figure 1A, also see supplemental Figure 
S2 at http://www.amjpathol.org). All 8 corresponded to fatal myocardial infarction (5 males, 3 
females, aged 60-80, death within 48h of the onset of clinical event).  
 
CD68 immunostaining identified fibrous cap and lipid core macrophages (Figure 1 B). Two-
color immunostaining with CD163 and HLA-DR revealed that these were either 
predominantly CD163highHLA-DRlow or CD163lowHLA-DRhigh (Figure 1 C,D). Double 
immunostaining for CD163 and the erythrocyte marker glycophorin-c indicated that the 
CD163high macrophages colocalised with plaque hemorrhage (Figure 1E). CD163lowHLA-
DRhigh cells were alpha-smooth muscle actin negative (Figure 1F). Findings were remarkably 
consistent in all eight thrombosed hemorrhaged plaques: 75±2.4% macrophages were 
CD163lowHLA-DRhigh and 25±2.9*% were CD163highHLA-DRlow (Figure 1G). We identified 
minimal numbers of CD68posCD163lowHLA-DRlow cells (Figure 1G). While CD163highHLA-
DRlow macrophages were consistently found in culprit lesions (see images at supplemental 
Figure S3 at http://www.amjpathol.org
.), twenty consecutive stable plaques from the same 
study contained only pro-inflammatory CD163lowHLA-DRhigh macrophages (not shown).  
 
We then assessed whether the CD163highHLA-DRlow and CD163lowHLA-DRhigh cells were 
definitively CD68pos macrophages. We used confocal immunofluorescence to analyse all 
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three markers simultaneously and relate them to lesion topography (see supplemental Figure 
S4 at http://www.amjpathol.org.). Two collections of CD68 positive macrophages are shown. 
One subset is  mixed with hemorrhage, ie. extravasated erythrocytes, and is characterized by 
high CD163 and a low HLA-DR (i.e. CD68posCD163highHLA-DRlow). In contrast, 
macrophages more distant to hemorrhage were conventional foam cells (FC), with an 
abundant foamy cytoplasm and  high HLA-DR but low CD163 (CD68posCD163lowHLA-
DRhigh. These observations therefore define a novel subset of CD68posCD163highHLA-DRlow 
hemorrhage-associated macrophages (HA-mac).  
 HA-mac are protected from oxidant stress despite iron loading 
We next characterized the possible pathophysiological role of HA-macrophages by assessing 
oxidant stress with antibodies specific for oxygen-adducted guanosine (8-oxo-guanosine; 
8oxoG) (32). While foam cell (FC) macrophages contained 8oxoG, as reported (32), HA- 
macrophages in the same sections were 8oxoG negative, indicating reduced oxidative stress 
(Figure 2A). Reduced HA-mac oxidative stress was in the face of increased loading with iron 
(a pro-oxidant catalyst), evidenced by ????????????????ouble-staining (Figure 2A). In serial 
sections, HA- macrophages reciprocally expressed HO-1 strongly and myeloperoxidase 
weakly (Figure 2A). FC macrophages had the reverse pattern (Figure 2A). CD163high 
macrophages were found adjacent to extravasated erythrocytes and intraplaque microvessels 
and co-expressed IL10 (Figure 2B-D).  
 
These associations were tested statistically. We measured distances of the two macrophage 
populations, HA-mac (CD163highHLA-DRlow) and FC-mac (CD163lowHLA-DRhigh ) to key 
plaque features (Table 1). FC-mac were closer to the lipid core ????????????????????????
S.E.]) than were HA-mac ??????????????????????Wilcoxon). In contrast, HA-mac 
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preferentially localized to CD34+ neovessels (p<0.005, Wilcoxon) and hemorrhage (p<0.01, 
Wilcoxon??????????????????????????????????????????????????????????(i.e. from Hb) in HA-mac but 
not FC-mac (p<0.05, Wilcoxon). HO-1 expression, quantified by image analysis, was higher 
in HA-mac than in FC-mac (p<0.01, Wilcoxon). In contrast, 8oxoG was significantly reduced 
in the HA-mac vs. FC-mac (p<0.01, Wilcoxon). IL10 expression, quantified by image 
analysis, was higher in CD163highHLA-DRlow (HA) than in CD163lowHLA-DRhigh (FC) 
macrophages (p<0.001, Wilcoxon). 
 
 
Differentiation of human monocytes with HbHp complexes reproduces HA-mac  
Using flow cytometric analysis of peripheral blood monocytes, we demonstrated that 
approximately 90% were CD14highCD16null and 10% were CD14lowCD16pos in keeping with 
previous reports (24). CD163 expression was restricted to monocytes, and there was no 
detectable difference in CD163 expression between the CD14lowCD16pos and 
CD14highCD16null subsets (see supplemental Figure S5 at http://www.amjpathol.org.). 
 
Whether HbHp complexes induce the CD163highHLA-DRlow phenotype was tested by 
culturing human monocytes for eight days in the presence of Hb, Hp or HbHp complexes 
(Figure 3). HbHp complexes (10-7mol.L-1), but neither constituent protein alone, induced a 
CD163highHLA-DRlow phenotype (Figure 3A-D). This effect was blocked separately by two 
antagonistic anti-CD163 antibodies (clones RM3/1, EdHu-1) (14), or by neutralising anti-
IL10 antibodies, but not by isotype-matched neutralising anti-TNF-? antibodies (Figure 3E-
H). These observations indicated dependence on CD163 and autocrine IL10 for 
CD163highHLA-DRlow polarization. This polarization was also blocked by specific inhibitors 
of phagocytosis or lysosomal processing (Figure 3 I-L): respectively cytochalasin-D 
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(phagocytosis inhibitor, 10-6 mol.L-1), chloroquine (lysosomal inhibitor, 10-6 mol.L-1), or 
pepstatin-A (lysosomal protease inhibitor, 10-9 to 10-6 mol.L-1). 
 
The prototypic pro-inflammatory stimuli IFN-? (5x10-8 mol.L-1, not shown) and LPS (1-
10ng.mL-1) prevented the HbHp-induced phenotype, producing CD163lowHLA-DRhigh cells 
even in the presence of HbHp (Figure 3M). Adenovirus (200MOI) also had this effect (not 
shown). In contrast, exogenous recombinant IL10 (5x10-11 mol.L-1 to 5x10-8 mol.L-1) evoked 
differentiation to the full CD163highHLA-DRlow phenotype (Figure 3N-R).  Dexamethasone 
(10-9mol.L-1 to 10-7mol.L-1; 1-100nM), a prototypic anti-inflammatory agent, increased 
CD163 and reduced HLA-DR, but not to the extent seen with HbHp complexes (Figure 3 S-
W). Hb freshly prepared by hypotonic lysis of autologous erythrocytes had the same effect as 
commercial Hb (see supplemental Figure S6 at http://www.amjpathol.org
complexes maximally induced CD163 at day 4, they needed to be added at culture outset for 
full induction, suggesting the programming of macrophage differentiation (see supplemental 
Figure S7 at http://www.amjpathol.org
.).  
 
 HA-mac are anti-inflammatory and antioxidant, and promote HbHp clearance in vitro 
We then investigated the anti-inflammatory and antioxidant phenotype of the in vitro 
differentiated HA-mac (Figure 4A-C). We examined pro- or anti-inflammatory cytokines, for 
reference comparing with dexamethasone (10-8mol.L-1) and LPS (10ng.mL-1) (Figure 4). 
HbHp complexes (10-7mol.L-1) or dexamethasone increased IL10 (Figure 4A) and increased 
the IL10/TNF ratio (Figure 4C), consistent with net anti-inflammatory activity. LPS 
increased TNF more than IL10, decreasing the IL10/TNF ratio, consistent with net pro-
inflammatory activation. Moreover, HA-mac had increased survival compared to control 
cultures (Figure 4D), and were more capable of clearing HbHp complexes relative to 
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untreated controls (Figure 4E). For concentration-effect curves for HbHp on IL10 secretion 
see supplemental Figure S8 at http://www.amjpathol.org. 
 
Since iron-loading may promote oxidant stress, we used multiple complementary readouts to 
assess whether HA-mac differentiation modulates production of reactive oxygen species 
(ROS). Compared to control day eight macrophages, H2O2 production was suppressed in HA-
mac, either in response to opsonised zymosan or to copper-oxidised low density lipoprotein 
(OxLDL) (Figure 4F,G). Hb-associated peroxidase activity was excluded as a confounder for 
H2O2 measurements (see supplemental Figure S9 at http://www.amjpathol.org).  Likewise, 
HA-mac were protected from phorbol-ester induced oxidant stress as measured by CM-
DCFDA fluorescence in the absence of serum (P<0.005, Figure 4H). H2O2 is converted to 
highly reactive oxygen species (hROS, specifically HONOO?, OH?, OCl-), which are 
selectively detected with APF (Methods, (27)). APF fluorescence indicated that HA-mac 
produced less hROS in response to OxLDL or serum deprivation (Figure 4I) or opsonised 
zymosan (not shown). Time-course and concentration-effect curves for these stimuli are given 
in supplemental Figure S9 at http://www.amjpathol.org. All the protective effects of HbHp 
were concentration-related and optimal at 10-7mol.L-1 (see supplemental Figure S10 at 
http://www.amjpathol.org). The protective response was reversed at the highest HbHp 
concentration, a feature we attribute to overload (the cultures were opaque red). 
 
CD163-siRNA specifically reduces Hb uptake, RM3/1 binding 
CD163-specific siRNA duplexes suppressed CD163, evidenced by western blotting using 
antibody GHI/61 (Supplemental Figure S11A at http://www.amjpathol.org). This 
corresponded to reduced RM3/1 surface binding ? even on a log scale (Supplemental Figure 
S11B). We measured uptake of AlexaFluor488-labelled HbHp complexes over 60 minutes 
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after addition to macrophage cultures (Supplemental Figure S11C). CD163-siRNA suppressed 
uptake of Alexa488-labelled HbHp complexes (Supplemental Figure S11D). RM3/1 also 
reduced Hb uptake, proving functional antagonistic activity  (Supplemental Figure S11E).  
Finally incubating the cells for four days with unlabelled HbHp complexes in the presence or 
absence of scramble or CD163-siRNA, showed that macrophage survival was reduced by 
CD163-knockdown; Supplemental Figure S11F).  
 
Non-linear  dynamics and exper imental validation show that HbHp / IL10 / CD163 
positive feedback evokes all-or -none commitment to CD163high versus CD163low 
phenotypes at a threshold concentration of HbHp complexes 
We observed that HbHp binding to CD163 leads to IL10 secretion, and that IL10 up-regulates 
CD163.  Since their output promotes their input, positive feedback loops are associated with 
exponential phenomena, as in the action potential or in pathophysiological vicious cycles. In 
contrast, positive feedback loops have been recently implicated in stable commitment to 
divergent states in T-helper cells (33). Here, the positive feedback loop enhances subset 
distinctiveness by abolishing intermediate states. More generally, similar regulatory 
architectures are being observed in a variety of systems biology contexts (29).  
 
We tested whether, in principle, a positive feedback loop between IL10 and CD163 in 
response to HbHp would generate discrete subsets governed by HbHp levels. We therefore 
constructed a proof of concept model. This is shown diagrammatically in Supplemental Figure 
S1 at http://ajp.amjpathol.org. We converted the diagram to a mathematical model to test 
whether a threshold level of HbHp switched the system between two lineages, deliberately 
keeping the model as simple as possible rather than providing a complete quantitative 
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description of the regulatory system. The model uses arbitrary variables and arbitrary 
parameters to probe a qualitative pattern of cell behaviour. 
 
In multiple simulations of equations (1) and (2) (see Methods), CD163 fell to negligible 
levels at low concentrations of HbHp, irrespective of starting concentrations (Figure 5A, blue 
curves). On the other hand, at HbHp concentrations above threshold, CD163 rose to a stable 
plateau with the level of final CD163 independent of initial CD163 (Figure 5A, red curves). 
Thus the model predicts that CD163-IL10 positive feedback leads to binary CD163high or 
CD163low phenotypes depending on HbHp input.  
 
The model was then used to predict behaviour of the final steady state levels of CD163 and 
IL10 with varying [HbHp] (Equations 3 and 4). Steady states occur when the concentrations 
of CD163 and IL10 do not change with time. These can be obtained by setting the left hand 
sides of the above equations to 0 and solving for [CD163] and [IL10]. This can be done 
algebraically. One set of solutions is simply [CD163]* = 0, [IL10]* = 0, corresponding to the 
low CD163 state. It is perhaps unrealistic that this is exactly at 0. However, if the state was a 
small non-zero level it would not affect any of the subsequent qualitative conclusions (e.g. by 
adding a small basal production rate to the above equations). We have chosen not to do this 
as it complicates the model, and in particular makes it impossible to obtain analytic 
expressions for the other steady state and the threshold in HbHp. With the equations as given, 
straightforward manipulation gives the other steady state as 
)        ([HbHp]k
kkkk)kkk[HbHp]([R]]*      [CD ddd 31163
1
221121 ???  
)         (]k([HbHpkk
kkkk)kkk[HbHp]([R]
   ]*        [IL
d
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221
2121121
?
???  
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Only non-negative values of protein levels are of biological relevance. For the above 
expressions to satisfy this constraint we require [R] > k1 k2 kd1 and [HbHp????H* where H* is 
the threshold given by 
                 5)
1
21
21
21
     (                              
kkk[R]
kkkk
    H*        
d
dd
??  
 
At [HbHp] = H
*
 the two steady states intersect in the well known transcritical bifurcation, 
exchanging stability (34). Further analysis shows that for [HbHp] < H
*
, the 0 steady state is 
stable and all solutions converge to it. At [HbHp] = H
*
 the 0 steady state loses stability. For 
[HbHp] > H
*
 it is the steady state given by Equations 3 and 4. 
 
Therefore, H* is the threshold level of HbHp. H* forms the boundary between the two CD163 
phenotypes. With [HbHp] below this value, CD163 levels drop to a steady state of negligible 
levels, irrespective of starting conditions (e.g. blue curves in Figure 5A). This is interpreted as 
the CD163lowHLA-DRhigh subset. In contrast, for [HbHp] above H* above the H* threshold, 
CD163 rises to a stable plateau, again irrespective of initial value. This corresponds to the red 
curves in Figure 5A and the CD163highHLA-DRlow subset. This threshold is shown in Figure 
5B. The final steady state level of CD163 rises rapidly as HbHp concentration reaches the 
threshold, before saturating at a fixed level. The simulations were run using a wide range of 
arbitrary parameters, and consistently gave these qualitative effects.   
 
Finally, we tested this prediction. We showed by flow cytometry that CD163 increased in an 
all-or-none manner at a threshold concentration of 10-9mol.L-1  (Figure 5C). It should be noted 
that the conceptual model uses arbitrary parameters, and does not predict the precise 
threshold. Moreover, the model was not designed to explore the effects of frank HbHp 
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overload. Evidence from plaques showing expression of IL-10 by HA-mac was also consistent 
with the predictions of the model (Table 1, Figure 2).   
 
Discussion 
Intraplaque hemorrhage (1;2) and plaque macrophages (35;36) play key roles in 
atherosclerotic lesion progression and vulnerability. We do not challenge this view, but 
instead define a novel macrophage subset HA-mac. These cells are identified within 
hemorrhaged inflamed lesions, and have several atheroprotective and compensatory 
properties. . Our data provide a logical extension of previous work on CD163, and add to 
conceptual understanding of macrophage subsets in relation to human vascular disease 
(10;13;37). 
 
Our in vitro data support that plaque hemorrhage adaptively modifies macrophage 
differentiation. Here, hemoglobin directs a discrete subset with increased hemoglobin uptake, 
reduced oxidant stress and generation of the anti-inflammatory cytokine IL10. This 
interpretation is biologically plausible, as it is an everyday observation that bruising is not 
itself inflammatory. However, since our starting material was post-mortem specimens, the 
phenomenon is self-evidently not fully atheroprotective. The HA-mac were a minority 
(approximately 25%), and conventional foamy macrophages predominated even in the plaques 
with large hemorrhages. Moreover, the known upregulation of HLA-DR by modified 
lipoproteins may accentuate the difference between the two subsets (FC vs HA) (38).  
Consistent with this, we have found that CD163high macrophages are absent in lesions with 
lipid core but no hemorrhage. 
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By defining a distinct macrophage subset, our data extend earlier descriptions that HO-1 and 
CD163 are found in atherosclerosis (13). Similarly, a substantial body of work, mainly by 
Levy and colleagues,  indicates that haptoglobin genotype Hp2-2 is less protective than Hp1-1 
in a wide range of vascular diseases (10;39).  We now give a mechanism contributing to these 
observations by defining how plaque hemorrhage drives a specific antioxidant hemorrhage-
associated macrophage subset. 
 
The concept of functionally distinct leukocyte subsets is well established for lymphocytes in 
vitro and in vivo (e.g CD4 vs CD8, Th1 vs Th2)(35). Macrophage subsets have been defined 
by in vitro differentiation with cytokines (37). Thus, classically-activated macrophages are 
generated by pro-atherogenic stimuli e.g.  IFN-?, TNF-?, and LPS,  and alternatively-activated 
macrophages are induced by IL-4 (37;40;41).  Loss of the key Th1 transcription factor T-bet 
suppresses macrophage HLA-DR in atherosclerosis in vivo, via reduction of CD4 T-helper 
derived IFN-??and increased IL-4 (42). This is consistent with a skew from classical to 
alternative activation, suggesting that classically activated plaque macrophages are pro-
atherogenic. However, HA-mac were characterised in the present study as more closely 
corresponding to the deactivated macrophage subset induced by IL10 or glucocorticoids (37). 
Interestingly, although dexamethasone upregulated CD163 and suppressed HLA-DR, we 
found that its effect was weak relative to that of HbHp (14;43). This may be in part related to 
different signalling pathways, since dexamethasone signals primarily via the glucocorticoid 
receptor, whilst  IL10 signals via silencer of cytokine signalling (SOCS) proteins, themselves 
therapeutic targets (43;44). Understanding different effects on macrophage function of 
glucocorticoids and HbHp therefore requires further study. 
 
  
24 
24 
Well established roles of macrophages in atherosclerosis include foam cell formation, lipid 
necrotic core formation, matrix metalloproteinase production, oxidant production and 
inflammatory cytokine secretion (35;36;45). However recent evidence describes active 
cholesterol export from the plaque via macrophage lymphatic emigration (46), or via the ABC 
pathway to HDL (47). This necessitates a more complex paradigm encompassing homeostatic 
macrophage roles. Our observations add to this by describing a non-lipid-driven macrophage 
homeostatic mechanism. 
 
We are not aware of a previous mathematical description of a bistable system driving 
macrophage differentiation, either in vascular disease or other situations. The non-linear 
dynamic modeling defined a role for the IL10 autocrine positive feedback loop. The key 
feature of the model is the stability produced by ?????????? saturability. At its simplest, this 
may equate to saturation of promoter regions of specific gene regulatory elements with 
transcription factors. The molecular nature of these effects is beyond the scope of the present 
paper but under active study. Critically, this feedback accurately predicted the existence of a 
threshold HbHp concentration for CD163 induction. Thus we experimentally validated the 
model at the qualitative level of all-or-none commitment to respective subsets. The system 
features positive feedback, threshold and an all-or-none response, which promote rapid 
decisive commitment. This permits the vascular wall to respond rapidly and consistently to 
sudden pro-oxidant threats such as plaque hemorrhage. We found experimentally that 6-8 days 
differentiation in 1?M HbHp concentrations reversed the protective phenotype, a feature 
consistent with toxicity from Hb overload. At this concentration, the cultures are 
macroscopically red and the cells brown. Thus this protective system can be overwhelmed, 
leading to maladaptive function.  
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In conclusion, we have characterised a novel atheroprotective macrophage subset (HA-mac) 
associated with intralesional hemorrhage. This subset contrasts strongly with pro-atherogenic 
conventional (classical) lipid core macrophages. HA-mac are adapted to swiftly clear Hb and 
contain oxidative stress. We predict that H-mac would suppress the impact of hemorrhage on 
atherosclerosis progression. In culprit lesions, the effects of HA-mac are by definition too 
little and too late, but therapeutic modification of HA-mac pathways may prevent plaque 
destabilisation.  
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Table 1 
 
Morphometric comparisons of the two macrophage subsets. Rows, data gathered in the 
same way (Methods) for HA-mac (CD163highHLA-DRlow)  and FC-mac (CD163lowHLA-
DRhigh). Columns, measurement of respectively: nearest distance to lipid core, nearest 
distance to microvessels, nearest distance to hemorrhage, cellular iron (where Figure 2D = 
3+), HO-1 staining intensity, 8-oxo-G staining intensity. 
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Figure Legends 
 
Figure 1 Human culpr it plaques contain a hemorrhage-associated macrophage subset 
Results are representative of eight ruptured plaques. Scalebars = 500?m. 
A. Hematoxylin and eosin (H&E), low power view of a culprit lesion with plaque rupture.  
T = thrombus. Arrow = plaque fissure.  
B. CD68 immunolabelling (immunoperoxidase-DAB, brown), using clone KP1. Clone PG-
M1 staining was equivalent. Arrow = plaque fissure. 
C. CD163 / HLA-DR double immunolabelling, low power. Blue = CD163, red = HLA-DR. 
Box = area shown at higher magnification in Panel C, which includes a fibrous cap 
infiltrated by macrophages and an area of hemorrhage. 
D. CD163 / HLA-DR double immunolabelling, high power. Blue = CD163, red = HLA-DR. 
FC = foam cell macrophages. HA = hemorrhage associated macrophages. Serial sections 
of these are also shown in zones HA & FC in Supplemental Figure S4.  
E. CD163 / erythrocyte (RBC) double immunolabelling. Blue = CD163, red = RBC marker 
glycophorin-c. T =thrombus. 
F. Alpha-smooth muscle actin immunolabelling (immunoperoxidase-DAB, brown). Arrow = 
plaque fissure. 
G. Quantification of subsets. Macrophages of each subset were counted and expressed as a 
proportion of macrophages in each lesion, and then summarised as mean and standard 
error for all 8 available ruptured plaques. * statistically significant distribution, ANOVA, 
p<10-8. 
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Figure 2.  
A. Reciprocal oxidative str ess and iron content in CD163high (HA-mac) and CD163low 
(foam cell) macrophages  Left hand column, photomicrographs of macrophages in 
area identified as hemorrhage-associated (HA). Right hand column, photomicrographs 
of macrophages in area identified as foam cell rich (FC). Scalebars = 40?m. Rows, 
immunolabeling as indicated, respectively for 8-oxo-guanosine (8-oxo-G); heme-
oxygenase-1 (HO-1) and myeloperoxidase (MPO). The bottom row are double-labeled 
for CD163 (re???????????????????????????????????????????????????????????????????????????he 
FC region are well described as OxLDL-derived ceroid (48). Brown is 
immunoperoxidase-DAB, and blue is hematoxylin counterstain.    
B-D. Ruptured plaque CD163+ macrophages, hemorrhage, iron and IL10.  
Images correspond to area HA of Panel A above, in serial sections, and are representative 
of the eight culprit plaques. Scalebars = 100?m. 
B. CD163 / RBCs. CD163 (blue immuno-alkaline phosphatase) / glycophorin C 
(erythrocytes, red immunoperoxidase) 
C. CD163 / CD34. CD163 (red immunoperoxidase) / CD34 (endothelial cells, blue 
immuno-alkaline phosphatase); 
D. ??????????????????????????????????. CD163 (red immunoperoxidase) / iron (blue, 
histochemistry ?????????????????? i.e. Prussian blue ferricyanide reaction). 
E. CD163 / IL10 CD163 (blue immuno-alkaline phosphatase) / IL10 (red 
immunoperoxidase). 
 
 
 
  
37 
37 
Figure 3. Mechanisms causally linking Hb to HA-mac phenotype  
Human peripheral blood monocytes were incubated in the presence of Hb, Hp, HbHp 
complexes, vehicle or cytokines or antagonists at concentrations as indicated. After 8 days 
of culture, macrophages were detached and dual stained for CD163 (FITC) and HLA-DR 
(PE). Representative flow cytometric dot plots are presented for at least five experiments 
from separate donors, with greater than twenty experiments examining the effects of 
HbHp complexes versus control. For each, the X-axis is CD163 and the Y-axis is HLA-
DR (isotype controls were in the first quadrant, not shown). The vehicle control for 
cytochalasin-D and chloroquine was DMSO. Dex = dexamethasone. Anti-TNF and anti-
IL10 = functionally antagonistic antibodies to TNF-? and IL10 respectively.  LPS = E.Coli 
lipopolysaccharide.  Hp:Hp complexes were used at 100 nM (10-7mol.L-1). Key: 
A. unstimulated culture of day 8 macrophages 
B. Incubated with HbHp complexes at 10-7mol.L-1 (100nM). 
C. Incubated with Hb at 10-7mol.L-1 (100nM). 
D. Incubated with Hp at 10-7mol.L-1 (100nM). 
E. As (B), with addition of anti-CD163 clone RM3/1 70nM. 
F. As (B), with addition of anti-CD163 clone EdHu-1 70nM. 
G. As (B), with addition of anti-IL10 Mab217 70nM. 
H. As (B), with addition of anti-TNF-? Mab225 70nM. 
I. As (B), with addition of DMSO 1:1000.  
J. As (B), with addition of 10-6M cytochalasin-D in DMSO, 1:1000. 
K. As (B), with addition of 10-6M chloroquine in DMSO, 1:1000.  
L. As (B), with addition of 10-7M, pepstatin-A in DMSO, 1:1000.  
M. As (B), with addition of LPS, 1ng/mL.  
N. Control (unstimulated) culture of macrophages at day8 
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O. Incubated with 5x10-11mol.L-1 (50pM) IL10 from outset of culture. 
P. As (O), but with 5x10-10mol.L-1 (500pM) IL10.  
Q. As (O), but with 5x10-9mol.L-1 (5nM) IL10.  
R. As (O), but with 5x10-8mol.L-1 (50nM) IL10. 
S. Unstimulated culture of macrophages at day8 
T. Incubated with 10-9mol.L-1 (1nM) dexamethasone from outset of culture. 
U. As (T), but with 10-8mol.L-1 (10nM) dexamethasone. 
V. As (T), but with 10-7mol.L-1 (100nM) dexamethasone. 
W. As (T), but with 10-6mol.L-1 (1?M) dexamethasone. 
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Figure 4 Homeostatic phenotype of HA-mac  
A-C, X-axes, respective stimuli, control medium (10% AHS IMDM); LPS - E.Coli 
lipopolysaccharide (10ng.mL-1), HbHp - HbHp complexes (100nM; 10-7mol.L-1), Dx - 
dexamethasone (10nM; 10-8mol.L-1). 
A. Y-axis, Absolute IL10 levels in supernatants in monocyte-macrophage cultures 24 
hours after addition of stimuli at the start of culture. (* ANOVA p<0.001 overall, with 
p<0.05 relative to control, Bonferroni adjusted post-test, values are mean + SEM of 
five donors.). 
B. Y-axis, Absolute TNF-? levels in supernatants in monocyte-macrophage cultures 24 
hours after addition of stimuli at the start of culture. (*ANOVA p=0.006 overall with 
p<0.05 relative to control, Bonferroni adjusted post-test, values are mean + SEM of 
five donors.). 
C. Y-axis, Ratio of IL10 / TNF in panels A and B. (* p=0.0001 ANOVA overall with 
p<0.05 relative to control with Bonferroni adjusted post-test, n=5 donors.). 
Concentration-effect curves (not shown) indicated that the direction of IL10 / TNF 
ratio was maintained at all concentrations of LPS (1-1000ng.mL-1) and HbHp (10-8 to 
10-6 mol.L-1) 
D. Y-axis, macrophage survival as measured by reduction of the colorimetric formazan 
dye MTS. Viability was measured relative to control cultures (100%). Control = 
unmodified 10% AHS IMDM; HbHp = 10-7mol.L-1?HbHp complexes added at the start 
?????????????????????????????????????????????????-test p=0.000143, values are mean + 
SEM of five donors.). 
E. Y-axis, Hb concentration in medium supernatant at 4 minutes after addition. X-axis, 
time after addition of HbHp complexes (10-7mol.L-1), measuring supernatant [Hb] 
spectrophometrically at 412nm. Open circles, macrophages were incubated in control 
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medium (10% AHS IMDM) for 8 days. Filled triangles, macrophages were 
differentiated with HbHp complexes (10-7mol.L-1) for 8 days. * significant difference, 
???????????-test p=0.000283.  
F. Y-axis, specific H2O2 production as measured by Amplex Red / peroxidase (Methods), 
calibrated by a H2O2 standard curve. Open bars, Control ? differentiation in 10% AHS 
IMDM for 8 days. Filled bars, HbHp ? differentiation in added HbHp complexes (10-
7
mol.L-1). X-axis, addition of opsonised zymosan, a prototypical macrophage oxidative 
burst stimulant, in 2 doses to control or HbHp differentiated macrophages. The dose of 
OpZ, is expressed as particles / well. Data are representative of five independent 
experiments using separate donors. ?????????????????????????????????????-test p=0.0017. 
G. Y-axis, H2O2 production as measured by Amplex Red / peroxidase, calibrated by a 
H2O2 standard curve. X-axis, addition of OxLDL (30?g.mL-1) to control or HbHp 
differentiated (10-7mol.L-1) macrophages. Open bars, Control ? differentiation in 10% 
AHS IMDM for 8 days. Filled bars, HbHp ? differentiation in added HbHp complexes 
(10-7mol.L-1). Data are representative of five independent experiments using separate 
donors. ?????????????????????????????????????-test p=0.034. 
H. Y-axis, oxidative stress as measured by DCFDA fluorescence in macrophages at 8 
days cultured in the presence or absence of HbHp (Methods). Data are representative 
of five independent experiments using separate donors. * significant difference, 
???????????-test p<0.005. 
I. Y-axis, highly reactive oxygen species (hROS), measured as fluorescence of the 
specific reporter amino-phenyl-fluorescein (APF) (Methods). Open bars, Control ? 
differentiation in 10% AHS IMDM for 8 days. Filled bars, HbHp ? differentiation in 
added HbHp complexes (10-7mol.L-1). X-axis, Cu-Ox-LDL, human LDL oxidised in 
10?mol.L-1 CuSO4 at 37?C for 18h, added at 30?g.mL-1. Serum deprivation ? medium 
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changed to matched IMDM without AHS. ?????????????????????????????????????-test p= 
9 x 10-5 (OxLDL) and p=3x10-6 (SFM). Data are representative of five independent 
experiments using separate donors. 
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Figure 5 Non linear  dynamics demonstrate that Hb-gated CD163-IL10 feedback dr ives 
switching to HA-mac phenotype   
A. Representative simulated time course of CD163 levels in a simple mathematical model 
describing the positive feedback loop between CD163 and IL10 given by Equations 1 
and 2, Supplementary Material Online (SOM). Both axes are in arbitrary units. Blue 
curves show the behaviour of CD163 for a low HbHp input ([HbHp] = 0.01 in 
?????????????????????????????????????????????????????????????????? ?????????????????
show behaviour for a high HbHp input ([HbHp] = 1) with the same starting levels. 
Other parameter values are [R] = 10, k1 = 1, k2 = 1, kd1 = 1, kd2 = 1 (arbitrary units) and 
the initial level of IL10 is 0.5 (arbitrary units) in all cases. The qualitative behaviour is 
independent of this choice, and similar threshold behaviour can be observed for all 
choices of k1 , k2 ,  kd1 and kd2 as long as the sensitivity of CD-163 to IL10 is sufficiently 
high ([R] > k1 k2 kd1 , SOM). 
B. Variation of final steady state values of CD163 and IL10 with HbHp input (all given in 
arbitrary units). Other parameter values are [R] = 10, k1 = 1, k2 = 12, kd1 = 0.75, kd2 = 
10-5 (arbitrary units). The steady states were obtained from Equations 3 and 4, SOM 
and clearly illustrate the threshold which for these parameter values occurs at H* = 
9 x 10-5. Similar qualitative behaviour is seen for all other parameter values as long as 
[R] > k1 k2 kd1 . 
C. Observed concentration-effect curves for HbHp complexes on CD163 levels by flow 
cytometry. X-axis, fluorescence intensity (CD163 staining (blue or red colors) or 
isotype control (grey). Y-axis, cell number. HbHp concentration in culture (expressed 
in mol.L-1) is given by the histogram color code as indicated.  To match Panel A, red 
colors are above threshold and the blue colors below threshold. The experiment is 
representative of n=5 donors.  
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Supplemental Figure Legends 
Supplemental Figure S1. Schematic proposed feedback loop between CD163 & IL10, 
gated by HbHp 
Molecular species are given in boxes. Arrows indicate causal increases. 
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Supplemental Figure S2 Thrombosis, hemorrhage and macrophage infiltration in 
human culpr it plaques  
Culprit lesions were defined as those which had caused the death of the patient, with 
histological evidence of disruption (plaque rupture, thrombosis, endothelial erosion 
denudation, macroscopic plaque hemorrhage >1mm). Scalebars, A - 1mm; B - 400?m; C- 
200?m; D - 100?m, E - 400?m; F - 100?m; T = thrombus. H = hemorrhage. LC = lipid core. 
FC = macrophage foam cell. Open arrow = neovessel containing erythrocytes. 
A-D. Photomicrographs of H&E sections of a representative culprit lesion (fibrous cap 
rupture) taken with objectives (A.) x4, (B.) x10 (C.) x20, (D.) x40. Each box represents the 
field chosen for the next higher magnification.  
E, F. Representative Hematoxylin and eosin (H&E), in a further 2 culprit lesions with 
occlusive thrombus due to endothelial erosion.  
 
Supplemental Figure S3. CD163/HLA-DR immunopositivity defines reciprocal subsets in 
multiple culpr it lesions  
Each image is a representative photomicrograph of a different culprit lesion immunolabelled 
with CD163 (blue) and HLA-DR (red). Scalebar = indicated distance. L = lumen (for 
orientation). 
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Supplemental Figure S4. Confocal analysis to define CD68posCD163highHLA-DRlow 
plaque macrophages.  
A, B: higher magnification micrographs of the culprit lesion in Figure 1 areas HA and FC, 
restained with H&E after confocal imaging. Blue arrowheads = RBC admixed with intimal 
extracellular matrix. Scalebars = 200?m 
C, D: Confocal scanning, under identical conditions for areas HA and FC. Individual 
confocal channels: Green CD68-FITC; Red CD163-AlexaFluor 647; Blue HLA-DR-
AlexaFluor 568; Orange 7-AAD nuclear dye. (H&E images) Scalebars = 20?m. 
E: Overlay of confocal images in C. Green = combined yellow and red = 
CD68posCD163highHLA-DRlow. 
F: Overlay of confocal images in D. Cyan = combined green and blue = 
CD68posCD163lowHLA-DRhigh. 
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Supplemental Figure S5. CD163 expression in CD14highCD16null and CD14dimCD16pos 
monocyte subsets 
Human peripheral blood monocytes were analysed immediately following isolation by three-
colour flow cytometry [CD14-PE (FL2), CD16-FITC (FL1), CD163-APC FL4)].  
A. Two-dimensional dotplot showing expression of CD14 (X-axis) versus expression of 
CD16 (Y-axis).  
B. CD163 expression in red gate, CD14hiCD16null. RFI- relative fluorescence intensity for 
specific CD163 staining. 
C. CD163 expression in blue gate, CD14dimCD16pos. RFI- relative fluorescence intensity for 
specific CD163 staining. 
 
 
Supplemental Figure S6. Effect of Hb from ster ile hypotonic lysis on monocyte subsets 
Erythrocytes were obtained from monocyte purification, subjected to hypotonic lysis in 50mL 
sterile endotoxin-free water (Invitrogen, tissue culture grade water). Cells were centrifuged at 
3000rpm to remove debris (sterile tissue culture 50mL centrifuge tubes), and the supernatant 
was collected. Hb concentration was determined by Soret peak spectrophometry, endotoxin-
free status by Limulus amebocyte assay and purity by SDS-PAGE and Coomassie staining. 
HbHp complexes were prepared and added at culture outset as for commercial Hb, after which 
the macrophages were cultured as before. Flow cytometry staining was as before (CD163-
FITC, HLA-DR-PE and isotype controls), but without dual-staining to obviate cytometer 
signal compensation.
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Supplemental Figure S7. Time course data for  expression of CD163  
A. Untreated macrophages. Horizontal axis - CD163 fluorescence intensity; vertical axis - 
cell number; axis into page, CD163 measured at indicated day. 
B. Macrophages treated with HbHp complexes at 10-7 mol.L-1. Horizontal axis - CD163 
fluorescence intensity; vertical axis - cell number; axis into page - CD163 measured at 
indicated day. 
C. Effect of delayed addition of HbHp complexes on final CD163. Horizontal axis - 
CD163 fluorescence intensity; vertical axis - cell number; axis into page ? day on 
which HbHp complexes were added. CD163 was measured at day 8. 
 
 
 
 
 
Supplemental Figure S8. Concentration-effect curves for  HbHp complexes on 
macrophage IL10 production. X-axis, HbHp concentration (log molar); Y-axis, supernatant 
IL10 levels from macrophage cultures at 24 hours, adding HbHp at culture outset. Levels are 
normalised by ratio to control wells (n=5 donors). (*p<0.05, significant increase ANOVA, 
Bonferroni). 
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Supplemental Figure S9. Assay validation, concentration-effect curves and time-course 
data for  stimuli for  macrophage respiratory burst  
A. X-axis, NaOCl concentration standards. Y-axis, fluorescence signal from 
aminophenylfluorescein (APF) at 535nm emission. AFU, arbitrary fluorescence units.   
B. X-axis, free-radical generating systems given in Table. SNP = sodium nitroprusside 
(NO donor); H2O2 = hydrogen peroxide; HRP = horseradish peroxidase; heme = ferric 
protoporphyrin. Concentrations as indicated. Y-axis, as (A). * p < 0.05, ANOVA with 
Bonferroni correction. 
C. X-axis, time in hours since start of serum deprivation. Y-axis, as (A).  
D. X-axis, concentration of added copper-oxidised low density lipoprotein (Cu-OxLDL), 
given in micrograms of protein per millilitre of medium (UV-spec). Y-axis, APF 
fluorescence corrected for cell number. *p<0.05 relative to control, ???????????-test. 
E. X-axis, concentration of Cu-OxLDL [as for (D)]. Y-axis, macrophage survival 
[normalised to control wells, formazan absorbance (Methods)]. *p<0.05 relative to 
control, ???????????-test. 
F. X-axis, H2O2 = hydrogen peroxide standard curve. Y-axis, fluorescence signal from 
Amplex Red peroxide-specific (peroxidase-catalysed) assay at 585-595nm emission, 
AFU=arbitrary fluorescence units. Open circles, control standard curve. Filled circles, 
addition of Hb at 100nM (concentration typically added to cells). 
G. X-axis, concentration of Cu-OxLDL [as for (D)]. Y-axis, hydrogen peroxide secretion, 
Amplex Red assay as F. (*p<0.05 relative to control, ???????????-test). 
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Supplemental Figure S10. Concentration-effect curves for  HbHp complexes.  
A-E Flow cytometry dot-plots of expression of CD163 (X-axis) versus HLA-DR (Y-axis. All 
are macrophages culture day 6 cultured in the presence or absence of HbHp complexes at the 
indicated concentrations from outset of culture to analysis. A, untreated; B, 1nm; C, 10nM; D, 
100nM; E, 1?M.  
F-I Macrophage functional assays. Macrophages were cultured for 6 days in 96-well 
microtitre plates with HbHp complexes at the indicated concentrations from the start to end. 
Anti-CD163=70nM antibody RM3/1.  
F: Y-axis, macrophage survival (formazan absorbance, A450nm normalised to control, 
Methods). X-axis, HbHp concentration (log molar); ?????????????????????????????????????? t-
test.  
G: Y-axis, macrophage survival (as for F). X-axis, 100nM of Hb only, Hp only, HbHp 
complexes, or HbHp complexes added after 70nM anti-CD163 clone RM3/1. *p<0.05 relative 
to control, ???????????-test. 
H: X-axis, HbHp concentration (log molar); Y-axis, oxidative stress (DCFDA fluorescence, 
AFU=arbitrary fluorescence units). *p<0.05 relative to control, ???????????-test.  
I: Y-axis, oxidative stress as in H. X-axis, specificity controls as in (G). *p<0.05 relative to 
????????????????????-test. 
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Supplemental Figure S11. CD163-specific siRNA downregulates RM3/1 binding, Hb 
uptake and reduces macrophage survival 
A. Western blotting, antibody GHI/61; ECL-plus detection. CD163 has an expected Mr ? 
120kDa. Control ? macrophages at culture day1 (0.1% AHS IMDM); CD163-siRNA; 
transfected with CD163-specific duplexes (Methods); scramble-siRNA; transfected 
with non-targeting duplexes; CHX- treated with cycloheximide 100?g/mL (positive 
control). The experiment is representative of three. 
B. Flow cytometry of macrophages treated with siRNA over 24 hours after isolation (as 
indicated). X-axis, binding of RM3/1 or isotype-control (as indicated). Gray and black 
curves, isotype-controls. Red, non-targeting RNA duplexes. Blue, CD163-duplexes. 
The experiment is representative of three. 
C. Time-course of uptake of Alexa488-labelled HbHp. X-axis, Hb uptake. Time-points 
as indicated on the image (gray, untreated; green, 4min; blue, 15min; pink, 30min; 
red, 60min). 60 mins was chosen for subsequent experiments. The experiment is 
representative of three. 
D. X-axis, Uptake of Alexa488-labelled HbHp uptake. Gray, untreated. Red, uptake by 
cells transfected with non-targetting RNA duplex. Blue, uptake by cells transfected 
with CD163-specific RNA duplex. The experiment is representative of three. 
E. X-axis, Uptake of Alexa488-labelled HbHp by macrophages. Red, uptake by cells in 
the presence of isotype-control (10?g/mL MOPC31C murine IgG1). Blue, uptake in 
the presence of RM3/1 (10?g/mL). The experiment is representative of three. 
F. Y-axis, macrophage survival at culture day 4, measured by XTT assay, normalised to 
control cells. HbHp, cultured in presence of 10-7mol.L-1 HbHp complexes. Scramble 
siRNA, transfected with nontargetting RNA duplexes. CD163-siRNA, transfected 
?????????????????????????????????????????????????????????-test.  
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